Aviceda Therapeutics
$207.5M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Aviceda Therapeutics is currently valued at $346.5M as of January 7, 2025. The company has raised a total of $276.3M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.25x, Aviceda Therapeutics has achieved a valuation that is 1.25 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
Aviceda Therapeutics's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Aviceda Therapeutics Worth in 2025?
As of 2025, Aviceda Therapeutics is valued at $346.5M, based on the company's Later Stage VC funding round in January 7, 2025. This valuation positions Aviceda Therapeutics as one of the leading private companies in the sector.
Aviceda Therapeutics Valuation History
Aviceda Therapeutics's funding history demonstrates steady growth and investor confidence.
How Aviceda Therapeutics Valuation is Determined
Private company valuations like Aviceda Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Aviceda Therapeutics Valuation FAQs
Is Aviceda Therapeutics profitable?
Aviceda Therapeutics has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Aviceda Therapeutics's valuation compare to competitors?
Aviceda Therapeutics is valued at $346.5M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Aviceda Therapeutics IPO?
Aviceda Therapeutics has not announced plans for an initial public offering. Until an IPO, investors can access Aviceda Therapeutics shares through secondary market platforms.